Evidence map›Paper›PMID 37543096›Full record

ReviewPharmacological research2023

New therapies towards a better glycemic control in youths with type 1 diabetes.

Roque Cardona-Hernandez, Klemen Dôvc, Torben Biester, Laya Ekhlaspour, Maddalena Macedoni, Martin Tauschmann, Chiara Mameli

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacological research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 6 countries.

Roque Cardona-HernandezDivision of Pediatric Endocrinology. Hospital Sant Joan de Déu, Barcelona, Spain.
Klemen DôvcFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, Ljubljana, Slovenia.
Torben BiesterAUF DER BULT, Diabetes Center for Children and Adolescents, Hannover, Germany.
Laya EkhlaspourDepartment of Pediatrics, Division of Endocrinology. University of California, San Francisco, CA, United States.
Maddalena MacedoniDepartment of Pediatrics, V. Buzzi Children's Hospital, Milan, Italy.
Martin TauschmannDepartment of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Chiara MameliDepartment of Pediatrics, V. Buzzi Children's Hospital, Milan, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. Electronic address: chiara.mameli@unimi.it.
Hospital Sant Joan de Déu Barcelona · ESKinderkrankenhaus auf der Bult · DEMedical University of Vienna · ATOspedale dei Bambini Vittore Buzzi · ITUniversity of California, San Francisco · USUniversity of Ljubljana · SIUniversity of Milan · IT

Funding

NIDDK NIH HHS K23 DK121942
6 · The paper itself

Abstract

Type 1 diabetes (T1D) is the most frequent form of diabetes in pediatric age, affecting more than 1.5 million people younger than age 20 years worldwide. Early and intensive control of diabetes provides continued protection against both microvascular and macrovascular complications, enhances growth, and ensures normal pubertal development. In the absence of definitive reversal therapy for this disease, achieving and maintaining the recommended glycemic targets is crucial. In the last 30 years, enormous progress has been made using technology to better treat T1D. In spite of this progress, the majority of children, adolescents and young adults do not reach the recommended targets for glycemic control and assume a considerable burden each day. The development of promising new therapeutic advances, such as more physiologic insulin analogues, pioneering diabetes technology including continuous glucose monitoring and closed loop systems as well as new adjuvant drugs, anticipate a new paradigm in T1D management over the next few years. This review presents insights into current management of T1D in youths.

Indexed as

Diabetes Mellitus, Type 1AdolescentAdultBlood GlucoseBlood Glucose Self-MonitoringChildGlycemic ControlHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsYoung AdultBlood GlucoseHypoglycemic AgentsInsulinAutomated insulin deliveryChildrenTechnologyTime in rangeType 1 diabetesYouths

Identifiers

PMID37543096
PMCPMC11073821
OpenAlexW4385554613

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.